Discovery

Shilpa Medicare has demonstrated robust capabilities in the biopharmaceuticals segment with ongoing developments in biosimilars like Aflibercept and innovative biological entities such as recombinant human albumin. The company is strategically investing in biosimilar pipeline expansions, advancing multiple blockbuster biologics, and leveraging its biologics CDMO services, which indicate a significant focus in biotechnology.

Aurobindo Pharma is advancing in the biosimilars space with a portfolio addressing a market opportunity of over $50 billion USD. The company received market authorization for Trastuzumab biosimilar in India and other approvals, signaling clear strategic intent and capability in biosimilars, including launching new products and expanding pipelines.

Concord Biotech has a strong focus on fermentation-based manufacturing of APIs, particularly immunosuppressants and oncology drugs, making significant contributions to the global biopharma space including regulated markets such as the US, EU, and Japan. Their R&D investments and collaboration efforts aim to enhance their biotechnology capabilities, positioning them as influential players in innovative pharmaceutical development.

Natco Pharma has a significant portfolio in oncology and has developed generic alternatives to patented biotech drugs like Revlimid, Sorafenib, and others. They continue to actively engage in R&D and legal pathways for biotech drugs, including recent significant profits from products like Revlimid in the US market.

Biocon Limited has significant strategic involvement in the biotechnology sector, particularly with its focus on biosimilars and novel biologics development. The company has demonstrated clear strategic intent by expanding its biosimilars portfolio, securing important regulatory approvals, and maintaining strong R&D investments in this area to drive mid to long-term growth.

Wockhardt is positioned as a major player in the pharmaceutical and biotechnology sectors, with a significant focus on the development of novel antibiotics targeting superbugs. Their research initiatives include patented biotechnology against drug-resistant infections, most notably their Qualified Infectious Disease Product (QIDP) status for multiple anti-bacterial discovery programs.

Advanced Enzyme Technologies Limited is a global leader in manufacturing enzymes and probiotics, having successfully scaled up technologies for their production. With a wide market application, including health care, animal nutrition, and food processing industries, its focus on developing newer enzyme applications signifies a robust presence in the biotechnology space.

Godavari Biorefineries is actively engaged in researching a new drug for triple-negative breast cancer. The company has successfully completed pre-clinical trials and obtained approval from the Central Drugs Standard Control Organisation for safety trials. This strategic move into biotech drug discovery, while non-core, signals their pursuit of innovation beyond their traditional bio-based chemical operations.

Kwality Pharmaceuticals has developed innovative drug delivery systems such as liposomal injectables, long-acting injectables, and other complex formulations that include peptide-based and biological injectables, signaling its significant involvement in the biotechnology sector. The company’s R&D capabilities and its strategic focus on biologics denote a strong commitment to innovation and biotechnology at a commercial scale.

Anthem Biosciences Limited is deeply engaged in the development and manufacturing of biotechnology-driven products, including high-potency biologically active peptides and biologically derived catalysts, which are essential in the pharmaceutical and specialty chemical industries. They have significant R&D capabilities in biologics, positioning them effectively in the biotech sphere.

Dr. Reddy's Laboratories is significantly involved in developing complex generics, biosimilars like Semaglutide, Abatacept, and proteins such as the GLP-1 group. Their strategic collaborations, like with Alvotech for pembrolizumab, emphasize their strong biotechnology focus. They are advancing critical pipeline programs reflecting an intense focus on biosimilars and innovative therapies, positioning for long-term growth in the biotechnology space.

Hester Biosciences is heavily involved in the biotechnology sector through its focus on developing and manufacturing animal vaccines, which involve complex biotechnological processes. The company's dedication to R&D and innovative approaches in vaccine development reflects its strong position in this thematic bucket.

PI Industries is actively investing in its biologicals business, leveraging a peptides-based biological technology platform for unmet grower needs globally. Recent developments include a new biological research centre in Hyderabad and an emphasis on biological product market expansion, demonstrating PI Industries' commitment to scale this biotechnology segment significantly.

SMS Pharmaceuticals Limited has reinforced its fundamental strength by maintaining FDA-compliant facilities and successfully completing audits with the US FDA at multiple facilities, showcasing strong capabilities in pharmaceutical manufacturing and biotechnology. The company's focus on producing high-value APIs, including anti-diabetic and anti-epileptic therapies, implies significant involvement in the biotechnology sector.

Lupin Limited is actively involved in the development of biosimilar products and has a robust pipeline of biosimilars. The company plans to have five key biosimilars in the market by fiscal year '30 and is actively working on biosimilars like Ranibizumab and Pegfilgrastim. Its strategic focus on this sector, along with regulatory developments and commercial strategy, positions Lupin as a significant player in biotechnology.

3B BlackBio Dx Limited is actively engaged in developing molecular diagnostics products, with a strong focus on PCR kits, NGS assays, and rapid tests for various serious illnesses. Their TRUPCR brand demonstrates an extensive product portfolio in infectious diseases, cancer detection, and AMR, highlighting their significant contribution to the biotechnology domain.

Glenmark Pharmaceuticals has significantly progressed its biotech initiatives, as showcased by the ISB 2001 agreement with AbbVie valued at $1.925 billion. This deal highlights Glenmark's substantial involvement in the development of novel biotech drugs targeting multiple myeloma, transforming the company into a self-sustaining biotech entity with a robust pipeline and improving financial thrust.

Jubilant Pharmova exemplifies strategic intent in biotechnology through its focused efforts in developing precision medicines within its proprietary novel drugs segment. The company is actively engaged in clinical trials for transformative treatments like JBI-802 and JBI-778, targeting oncology and autoimmune diseases, thereby positioning itself as a leader in biotech advancements.

Laurus Labs is expanding its capabilities in the biotechnology sector with an operational gene therapy and antibody-drug conjugate process development lab in Hyderabad. The company is also constructing a cGMP facility for gene/ADC therapy, reflecting a strategic focus on advancing biotech solutions and tapping into this high-growth sector.

Syngene International Limited is a prominent player in the biotechnology sector, offering comprehensive services across the drug development lifecycle. They have expanded their collaboration with Bristol-Myers Squibb to include drug discovery, development, and manufacturing until 2035. This long-term partnership is a testament to their strategic expertise and significance in the biotechnology industry.

Rubicon Research Limited is heavily focused on developing innovative pharmaceutical solutions and has demonstrated a strong R&D pipeline with products targeting regulated markets, particularly the United States. This emphasis on specialty products, drug-device combinations, and an array of 74 active ANDAs and 9 NDAs showcases Rubicon Research Limited's significant involvement in the biotechnology sector.

Onesource Specialty Pharma Limited has demonstrated significant growth in its biologics segment, with a robust pipeline and numerous ongoing projects. The company has strengthened its biosimilars capabilities, signed multiple MSAs, and expanded its customer base with global players in the biologics field. This strategic focus on biosimilars, alongside expanding capacities and capabilities, strongly positions Onesource in the biotechnology thematic bucket.

Dishman Carbogen Amcis is actively engaged in developing high-value CDMO offerings for biotech therapies, evidenced by its pipeline of 10 molecules in late-phase III and its integration across value chains. The company's robust R&D and global operational footprint in the US PII/III help drive biotech revenues, indicating its strong participation in the biotechnology sector.

Emcure Pharmaceuticals has developed a strong presence in both chemistry and biotech, making it a leader in biotechnology within India. The company boasts a portfolio of seven biotherapeutics marketed, two awaiting approval, and multiple others in development, underlining its strategic focus and scale in the biotech space. This positions Emcure as a significant player in the biotechnology bucket.

Suraksha Diagnostic Limited has established a CAP-validated, end-to-end genomics laboratory (cytogenetics, microarray, PCR, next-generation sequencing) and acquired a controlling stake in Fetomat to accelerate genomic offerings; the company is developing proprietary clinical assays including an HRD assay for ovarian cancer, demonstrating clear strategic intent and a material pivot into molecular diagnostics and translational biotech services.

Zydus Lifesciences demonstrates material biotech involvement: an active biosimilars portfolio (26 biosimilars including ADCs), ongoing Phase III approval for a second biosimilar ADC in India, licensing deals for large-molecule biosimilars (Pembrolizumab, Ranibizumab), and investments in biologics manufacturing through the acquisition of two California biologics facilities — all indicating biotech as a strategic, revenue-facing vertical for Zydus.

Alkem Laboratories has a material and strategic biotechnology footprint through its subsidiary Enzene Biosciences, a dedicated biologics/biosimilars business with an operational biologic manufacturing facility in Pune and launched biosimilars such as Cetuxa (cetuximab). Alkem has filed BLAs/NDAs and continues to invest in biologics R&D, signalling deliberate scaling of biotech as a long-term growth pillar for Alkem Laboratories.

Ipca Laboratories is materially engaged in biotech development: management disclosed five biosimilar candidates under development, technology transfer started for two products and regulatory protocol reviews have been taken with MHRA, European authorities and the U.S. FDA. Ipca Laboratories is positioning these biosimilars for global markets, reflecting a clear, funded strategic intent to commercialize biotech products across developed and emerging geographies.

Gufic Biosciences is actively investing in biotech R&D beyond formulations, including peptides, cyclopeptides and an in‑house immuno‑oncology program (Selvax SVX‑3001) that has delivered robust preclinical results and a canine Phase I proof‑of‑concept; the company has filed IP and is advancing cell line development, signalling strategic intent to commercialize biologics over the medium term.

Fermenta Biotech Limited demonstrates material biotechnology involvement through proprietary enzyme technologies, patented processes, and commercialization of biocatalysts; the company reports R&D outcomes such as Penmox enzyme, tripled enzyme activities, and enzymatic synthesis of Molnupiravir, indicating Fermenta Biotech Limited is developing IP and manufacturing-ready biotech solutions beyond pilot or internal automation.

Natural Capsules Limited has moved materially into fermentation‑based steroidal API manufacturing via its subsidiary Natural Biogenex Private Limited, developed in‑house patented processes and started commercial production activities by March 2025. The company has secured three PLI approvals for dexamethasone, betamethasone and prednisolone, positioning Natural Capsules Limited as a domestic manufacturer with unique microbial fermentation know‑how and granted patents.

Eris Lifesciences has made material moves into biologics: acquisition of Eris BioNxt (an EU‑GMP ready biologics drug products facility) and a strategic minority investment in Levim Lifetech focused on complex biologics and gene therapies. These transactions, combined with insulin and GLP‑1 development and planned exports, position Eris as a meaningful biotechnology and biologics-manufacturing player in India.

Sanofi India positions itself as an R&D-driven organization with material clinical and real‑world efforts: LANDMARC enrolled 6,236 patients across 382 sites and the Soliqua Phase IV last‑patient‑in milestone was recorded, while the presentation lists advanced molecules (teplizumab, brivekimig, frexalimab) tied to diabetes indications; these activities indicate substantive local biotech clinical and evidence-generation scale for Sanofi India.